



# LORAZEPAM 0.5mg Tablets

- **Indicated for** short-term use (2-4 weeks only) in adults. The medication provide symptomatic relief of severe anxiety, either alone or in association with insomnia or short-term psychosomatic, organic, or psychotic illness.
- Additionally, it can be used as premedication for adults and children aged 5 years and above before operative dentistry and general surgery.

Available strength: 0.5mg

## Lorazepam 0.5mg is specifically indicated for patients with renal or hepatic impairment.

- Patients with impaired renal or hepatic function are recommended to take lower doses, as per SmPC for Lorazepam.

## Reference markets

- Lorazepam continues to be a cornerstone therapy, with sales of 2.1 billion tablets (MAT Q2 2022) and a growing presence, as reported by IQVIA in the EU27+UK.

The product strength addresses a therapy gap

For patients with renal or hepatic impairment



### Regulatory pathway

- Legal basis: Article 10(3) hybrid application


### Development status



- UK dossier is available. UK submission is planned for 10/2023.

## Partnership options

- The product is available for out-licensing in select European markets
- The product is also available for licensing outside of Europe

**DISCLAIMER:** Any disposal with the product, including but not limited to the development, sale and offer for sale of products and related processes identified within this catalogue is performed by Zentiva only in those territories where it is permissible by applicable patent law; in particular, but not limited to Art. 10 EC Directive 2001/83. This catalogue shall not constitute an offer for sale of products and processes for the territories where an offer for sale or sale is not permissible by law. Zentiva expressly disclaims any liability for damages resulting from or arising out of the unauthorised use of such products and related processes.

 Zentiva Group a.s.  
U Kabelovny529/16, 102 00 Prague 10, Czech Republic

 [Zent2U@zentiva.com](mailto:Zent2U@zentiva.com)  
 +420 267243231

 [www.Zent2U.com](http://www.Zent2U.com)

**ZENTIVA**